Cargando…
Antisecretory Factor May Reduce ICP in Severe TBI—A Case Series
Traumatic brain injury (TBI) constitutes a global epidemic. Overall outcome is poor, with mortality ranging from 10 to 70% and significant long-term morbidity. Several experimental reports have claimed effect on traumatic edema, but all clinical trials have failed. Antisecretory factor, an endogenou...
Autores principales: | Cederberg, David, Hansson, Hans-Arne, Visse, Edward, Siesjö, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067821/ https://www.ncbi.nlm.nih.gov/pubmed/32210902 http://dx.doi.org/10.3389/fneur.2020.00095 |
Ejemplares similares
-
Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma
por: Ehinger, Erik, et al.
Publicado: (2023) -
Intratumoral administration of the antisecretory peptide AF16 cures murine gliomas and modulates macrophage functions
por: Kopecky, Jan, et al.
Publicado: (2022) -
Effect of antisecretory factor, given as a food supplement to adult patients with severe traumatic brain injury (SASAT): protocol for an exploratory randomized double blind placebo-controlled trial
por: Cederberg, David, et al.
Publicado: (2022) -
Does the antisecretory peptide AF-16 reduce lung oedema in experimental
ARDS?
por: Barrueta Tenhunen, Annelie, et al.
Publicado: (2019) -
The antisecretory peptide AF-16 may modulate tissue edema but not inflammation in experimental peritonitis induced sepsis
por: Barrueta Tenhunen, Annelie, et al.
Publicado: (2020)